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 Gastric cancer is one of the most prevalent cancers 
worldwide, ranking fourth after lung, breast and colorectal 
cancers, and it is the second cause of cancer death. The 
majority of cases occur in developing countries and are 
more common in males, irrespective of age and geographic 
area. In Portugal it ranks fifth in cancer deaths and its inci-
dence is the highest in Western Europe.
 The most common type of gastric cancer is adeno-
carcinoma, whose prevalence is related to male gender, 
increasing age and high prevalence regions, indicating 
environmental factors as risk factors for the disease. The 
accepted model for development of this type of cancer in-
volves a cascade of premalignant conditions occurring over 
several years, due to environmental and host factors, which 
might progress to premalignant lesions (e.g. dysplasia) and 
invasive cancer.
 Several observational studies have shown that environ-
mental factors play a part and salt, nitrates, tobacco and 
Helicobacter pylori are the most fully described agents. Heli-
cobacter pylori  is the single main risk factor and considered 
to promote the development of these precursor conditions 
and lesions. The first of these may be gastric inflammation 
that progresses to loss of appropriate glands (atrophy), 
replacement of original glands with intestinal metaplasia 
glands that might develop into dysplasia and finally into 
invasive carcinoma. It is considered that their intragastric 
extension is also relevant in patients presenting with atro-
phy or intestinal metaplasia in the corpus, who represent a 
subgroup of higher risk patients for whom a specific surveil-
lance programme is recommended.
 Host factors, in particular genes that regulate expres-
sion of proinflammatory agents (interleukin 1 β, tumour-
necrosis factor) and some innate immunity receptors such 
as toll-like receptors (TLRs) have been linked to gastric car-
cinogenesis but as yet without proven clinical implications. 
Studies comparing the expression of TLRs and their inhibi-
tors in all premalignant lesions of the gastric carcinogenesis 
cascade have provided a statistically significant trend for a 
decrease of TLR inhibitors and a progressive increase of 
TLR expression, in particular 0.1 for normal mucosa, 1.0 for 
gastritis, 2.2 for intestinal metaplasia and 2.8 for dysplasia 
(p < 0.001).1-4 Familial aggregation of gastric cancer might 
have some role in about 10% of cases, in particular in first 
relatives of early onset gastric cancer patients.  In a case-
control study these first degree relatives of gastric cancer 
patients presented an increased prevalence of Helicobacter 
pylori infection (82% versus 65%, p = 0.001) and extensive 
atrophic gastritis or intestinal metaplasia (19% versus 0%, 
p < 0.001). These results are corroborated in the literature 
and seem to be independent of the source of controls used, 
reinforcing the recommendation for screening and treating 
for Helicobacter pylori in these cases and suggesting that a 
specific surveillance might be desirable, although this is still 
not consensual.5,6 Serologic measurement of pepsinogens 
I and II, normally produced in the gastric mucosa, could be 
used to screen for high-risk patients harbouring extensive 
premalignant conditions (e.g. detection of atrophy and/or 
intestinal metaplasia both in antrum and corpus).7 It was 
determined in several studies and in a recent meta-analysis 
that a pepsinogen I value ≤ 70 and a pepsinogen I versus II 
ratio ≤ 3 had a sensitivity of 77% and a negative predictive 
value of 99% for the diagnosis of dysplasia.8
 For the endoscopic diagnosis of these premalignant 
lesions, conventional endoscopy does not present the re-
quired accuracy or reproducibility to preclude the need for 
taking biopsies: even in normal-appearing gastric mucosa, 
patients with a median pepsinogen I/II ratio of 2.8 have 
intestinal metaplasia in both the antrum and corpus, and 
with a ratio of 1.8 more than 50% of the antrum will harbour 
intestinal metaplasia.9 Because of this lack of accuracy of 
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conventional endoscopy, a detailed endoscopic inspection 
should be backed up with biopsies. These should involve a 
minimum of two samples from the gastric antrum and two 
separate samples from the body, plus biopsies of any suspi-
cious lesions identified.10
 Recent endoscopic advances such as chromoendos-
copy with methylene blue or narrow band imaging are bet-
ter in terms of both diagnostic accuracy and reproducibility 
than conventional endoscopy and their use could be jus-
tified for the surveillance of a high risk population.11 Con-
ventional chromoendoscopy with 1% methylene blue gave 
a diagnosis of dysplasia with a specificity of 81% (95% 
confidence interval [CI]: 77-85%) and a negative predic-
tive value of 99% (95% CI: 99-100%) along with a kappa 
statistic of 0.86 for intraobserver and 0.74 for interobserver 
agreements.12 These values were validated in another cen-
tre which provided very similar results for the diagnosis of 
dysplasia (sensitivity of 100%, specificity of 99%) and for 
reproducibility (kappa 0.92, 95% CI: 0.88-0.96) for classifi-
cation in groups).13 Electronic chromoendoscopy by narrow 
band imaging for gastric precursor lesions has been evalu-
ated in several studies, providing different classifications 
that were combined in a simplified classification. This was 
prospectively validated in a multicenter endoscopic study, 
providing diagnostic accuracies for normal mucosa of 83% 
(95% CI: 75-90%), intestinal metaplasia of 84% (95% CI: 
77-91%) and dysplasia of 95% (95% CI: 90-99%). The 
global reproducibility was kappa = 0.62 and varied between 
experienced versus non-experienced endoscopists (0.75 
versus 0.60).14
 Screening for gastric cancer is only cost-effective in high 
risk countries but in those countries, like Portugal, with an 
intermediate incidence of this disease, high-risk patients 
could be offered a specific surveillance programme. These 
high-risk patients present extensive atrophy or intestinal 
metaplasia involving the antrum and corpus, diagnosed 
by pepsinogen assessment or endoscopic biopsy as sug-
gested in a recent consensus guideline.10 In these cases, 
endoscopic surveillance should be offered on a 3-yearly 
endoscopic schedule, supplemented with magnification 
chromoendoscopy or narrow-band imaging if available. If, 
whilst under surveillance, dysplasia is detected without a 
visible endoscopic lesion, close follow-up should be offered, 
either immediately in high grade cases or within 12 months 
for those with low grade. Patients with dysplasia or cancer 
within an endoscopically visible lesion should undergo sta-
ging and resection.10,15
 This suggestion of surveillance of patients with prema-
lignant conditions has only been evaluated by 3 cost-effec-
tiveness studies and a recent review showed the results in 
the available literature to be contradictory (probably due to 
different assumptions on progression of precursor condi-
tions). While the incremental cost-effectiveness ratio varied 
between 1 868 and 72 519 US dollars for intestinal meta-
plasia (crossing the usually accepted threshold of 50 000 
US dollars), for dysplasia incremental values ranged only 
between 18 600 and 39 800 US dollars. Although the evi-
dence so far is slight, for dysplasia close follow-up seems 
to be the consensual approach for clinical and cost-effective 
purposes.16,17
 In conclusion, gastric cancer is still a prevalent cancer 
worldwide and a health problem in several countries but dif-
ferent incident rates should lead to different attitudes. While 
in the Western world population screening is not cost-effec-
tive, screening for high-risk patients could lead to a better 
resource allocation and it could be done either by family his-
tory (especially in first relatives of early onset gastric cancer 
patients), serologic pepsinogen measurement or endosco-
pic evaluation with biopsies from the antrum and corpus.
 For those patients harbouring a high-risk condition such 
as extensive atrophy or intestinal metaplasia in both the an-
trum and corpus, our attention and dedication should be un-
wavering and, although the results from cost-effectiveness 
studies are contradictory, our best endoscopic surveillance 
should be offered on a 3-yearly basis, alongside magnifi-
cation chromoendoscopy or narrow-band imaging, if avai-
lable.
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